Read by QxMD icon Read

Luminal a breast cancer radiation

Pang-Kuo Lo, Benjamin Wolfson, Qun Zhou
Ductal carcinoma in situ (DCIS) is a category of early stage, non-invasive breast tumor defined by the intraductal proliferation of malignant breast epithelial cells. DCIS is a heterogeneous disease composed of multiple molecular subtypes including luminal, HER2 and basal-like types, which are characterized by immunohistochemical analyses and gene expression profiling. Following surgical and radiation therapies, patients with luminal-type, estrogen receptor-positive DCIS breast tumors can benefit from adjuvant endocrine-based treatment...
May 10, 2016: World Journal of Obstetrics and Gynecology
Jacob A Miller, Rupesh Kotecha, Manmeet S Ahluwalia, Alireza M Mohammadi, Samuel T Chao, Gene H Barnett, Erin S Murphy, Michael A Vogelbaum, Lilyana Angelov, David M Peereboom, John H Suh
BACKGROUND: The current study was conducted to investigate survival and the response to radiotherapy among patients with molecular subtypes of breast cancer brain metastases treated with or without targeted therapies. METHODS: Patients diagnosed with breast cancer brain metastases at a single tertiary care institution were included. The primary outcome was overall survival, whereas secondary outcomes included the cumulative incidences of distant intracranial failure, local failure, and radiation necrosis...
February 13, 2017: Cancer
Soichiro Ueno, Takashi Nakakuma, Osamu Murata, Norihiko Sengoku, Kazuhiro Karikomi, Megumi Honma
Of the 210 patients who underwent breast-conserving surgery for breast cancer and received radiation therapy for 3 years from April 2012 to March 2015 at the Department of Therapeutic Radiology of our hospital, 6 were diagnosed with cryptogenic organizing pneumonia(COP)-like pneumonia and treated as reported. The mean age of the patients was 51years(40- 65 years), and the pathological subtypes were the luminal type(5 cases)and HER2 type(1case ), all of which were treated with radiation therapy for breast conservation...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
J Barrou, M Bannier, M Cohen, E Lambaudie, A Gonçalves, P Bertrand, M Buttarelli, P Opinel, N Sterkers, A Tallet, C Zinzindohoué, G Houvenaeghel
CONTEXT: Even if neoadjuvant chemotherapy (NACT) and oncoplastic techniques have increased the breast conserving surgery rate, mastectomy is still a standard for multifocal or extensive breast cancers (BC). In the prospect of increasing breast reconstruction, an alternative therapeutic protocol was developed combining NACT with neoadjuvant radiation therapy (NART), followed by mastectomy with immediate breast reconstruction (IBR). The oncological safety of this therapeutic plan still needs further exploration...
April 2017: Breast: Official Journal of the European Society of Mastology
Lars Johan Sandberg, Mark W Clemens, W F Symmans, Vicente Valero, Abigail S Caudle, Benjamin Smith, Henry M Kuerer, Limin Hsu, Steven J Kronowitz
BACKGROUND: Molecular profiling using breast cancer subtype has an increasing role in the multidisciplinary care of the breast cancer patient. We sought to determine the role of breast cancer subtyping in breast reconstruction and specifically if breast cancer subtyping can determine the need for postmastectomy radiation therapy (PMRT) and predict recurrence-free survival (RFS) to plan for the timing and technique of breast reconstruction. METHODS: We reviewed prospectively collected data from 1931 reconstructed breasts in breast cancer patients who underwent mastectomy between November 1999 and December 2012...
November 21, 2016: Plastic and Reconstructive Surgery
Sang-Won Kim, Mison Chun, Sehwan Han, Yong Sik Jung, Jin Hyuk Choi, Seok Yun Kang, Hyunee Yim, Seung Hee Kang
Purpose: The effects of biological subtypes within breast cancer on prognosis are influenced by age at diagnosis. We investigated the association of young age with loco-regional recurrence (LRR) between patients with luminal subtypes versus those with non-luminal subtypes. Materials and methods: Medical records of 524 breast cancer patients with positive lymph nodes between 1999 and 2010 were reviewed retrospectively. All patients received curative surgery and adjuvant chemotherapy based on contemporary guidelines...
August 23, 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
Naoki Nakamura, Satoko Arahira, Sadamoto Zenda, Kimiyasu Yoneyama, Hirofumi Mukai, Masakatsu Onozawa, Masamichi Toshima, Atsushi Motegi, Yasuhiro Hirano, Hidehiro Hojo, Yuichi Kibe, Tetsuo Akimoto
To clarify the efficacy and toxicity of post-mastectomy radiation therapy (PMRT) without usage of a bolus, we identified 129 consecutive patients who received PMRT at the National Cancer Center Hospital East between 2003 and 2012. Seven of the 129 patients who received breast reconstruction before PMRT were excluded. All patients received PMRT of 6 MV photons, without usage of a bolus. The median follow-up duration for all eligible patients was 47.7 months (range: 4.0-123.2). Local, locoregional and isolated locoregional recurrence was found in 12 (9...
January 2017: Journal of Radiation Research
Caterina Fontanella, Elisa De Carlo, Marika Cinausero, Giacomo Pelizzari, Ilaria Venuti, Fabio Puglisi
Central nervous system (CNS) involvement from breast cancer (BC) has been historically considered a relatively rare event. However, the development of new therapeutic strategies with a better control of extra-cranial disease and a longer overall survival (OS) has determined an increased incidence of brain metastases. Patients with HER2-positive or triple negative BC have higher occurrence of CNS involvement than patients with luminal-like disease. Moreover, after development of brain metastases, the prognosis is highly influenced by biological subtype...
May 2016: Cancer Treatment Reviews
Roman Mezencev, Lilya V Matyunina, Neda Jabbari, John F McDonald
BACKGROUND: Epithelial-to-mesenchymal transition (EMT) has been associated with the acquisition of metastatic potential and the resistance of cancer cells to therapeutic treatments. MCF-7 breast cancer cells engineered to constitutively express the zinc-finger transcriptional repressor gene Snail (MCF-7-Snail cells) have been previously shown to display morphological and molecular changes characteristic of EMT. We report here the results of a comprehensive systems level molecular analysis of changes in global patterns of gene expression and levels of glutathione and reactive oxygen species (ROS) in MCF-7-Snail cells and the consequence of these changes on the sensitivity of cells to radiation treatment and therapeutic drugs...
March 18, 2016: BMC Cancer
Ryota Tanaka, Kan Yonemori, Akihiro Hirakawa, Fumie Kinoshita, Naoki Takahashi, Jun Hashimoto, Makoto Kodaira, Harukaze Yamamoto, Mayu Yunokawa, Chikako Shimizu, Manabu Fujimoto, Yasuhiro Fujiwara, Kenji Tamura
BACKGROUND: Bone-modifying agents (BMAs) reduce the incidence of skeletal-related events (SREs) and are thus recommended for breast cancer patients with bone metastases. However, the risk factors for SREs during BMA treatment are not well-understood. This study evaluated the number and timing of SREs from case studies to identify these factors. METHODS: The medical records of 534 women with breast cancer who developed bone metastases between 1999 and 2011 were reviewed...
April 2016: Oncologist
M Tumiati, P M Munne, H Edgren, S Eldfors, A Hemmes, S G Kuznetsov
Almost half of all hereditary breast cancers (BCs) are associated with germ-line mutations in homologous recombination (HR) genes. However, the tumor phenotypes associated with different HR genes vary, making it difficult to define the role of HR in BC predisposition. To distinguish between HR-dependent and -independent features of BCs, we generated a mouse model in which an essential HR gene, Rad51c, is knocked-out specifically in epidermal tissues. Rad51c is one of the key mediators of HR and a well-known BC predisposition gene...
September 1, 2016: Oncogene
Eunjin Jwa, Kyung Hwan Shin, Hyeon Woo Lim, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, EunSook Lee, Young Hee Park
INTRODUCTION: The locoregional recurrence (LRR) rate was reported as high as approximately 20% in stage I-II breast cancer following mastectomy. To investigate the risk factors for LRR in pT1-2N0-1 breast cancer patients treated with mastectomy but not radiation, and to define a subgroup of patients at high risk of LRR who may benefit from postmastectomy radiotherapy (PMRT). METHODS AND MATERIALS: In total, 390 patients with pT1-2N0M0 (n = 307) and pT1-2N1M0 (n = 83) breast cancer who underwent total mastectomy without adjuvant radiotherapy from 2002 to 2011 were enrolled in the study...
2015: PloS One
Janet K Horton, Sharareh Siamakpour-Reihani, Chen-Ting Lee, Ying Zhou, Wei Chen, Joseph Geradts, Diane R Fels, Peter Hoang, Kathleen A Ashcraft, Jeff Groth, Hsiu-Ni Kung, Mark W Dewhirst, Jen-Tsan A Chi
Although a standardized approach to radiotherapy has been used to treat breast cancer, regardless of subtype (e.g., luminal, basal), recent clinical data suggest that radiation response may vary significantly among subtypes. We hypothesized that this clinical variability may be due, in part, to differences in cellular radiation response. In this study, we utilized RNA samples for microarray analysis from two sources: 1. Paired pre- and postirradiation breast tumor tissue from 32 early-stage breast cancer patients treated in our unique preoperative radiation Phase I trial; and 2...
November 2015: Radiation Research
Javier F Torres-Roca, William J Fulp, Jimmy J Caudell, Nicolas Servant, Marc A Bollet, Marc van de Vijver, Arash O Naghavi, Eleanor E Harris, Steven A Eschrich
PURPOSE: Recently, we developed radiosensitivity (RSI), a clinically validated molecular signature that estimates tumor radiosensitivity. In the present study, we tested whether integrating RSI with the molecular subtype refines the classification of local recurrence (LR) risk in breast cancer. METHODS AND MATERIALS: RSI and molecular subtype were evaluated in 343 patients treated with breast-conserving therapy that included whole-breast radiation therapy with or without a tumor bed boost (dose range 45-72 Gy)...
November 1, 2015: International Journal of Radiation Oncology, Biology, Physics
Yolanda D Tseng, Hajime Uno, Melissa E Hughes, Joyce C Niland, Yu-Ning Wong, Richard Theriault, Rachel C Blitzblau, Beverly Moy, Tara Breslin, Stephen B Edge, Michael J Hassett, Rinaa S Punglia
PURPOSE: To evaluate locoregional recurrence (LRR) after mastectomy and impact of postmastectomy radiation (PMRT) by breast cancer subtype. METHODS AND MATERIALS: Between 2000 and 2009, 5673 patients with stage I to III breast carcinoma underwent mastectomy and nodal evaluation; 30% received PMRT. Isolated LRR (iLRR) and LRR were compared across groups defined by biological subtype and receipt of trastuzumab: luminal A (estrogen [ER]/progesterone [PR]+, HER2-, low/intermediate grade), luminal B (ER/PR+, HER2-, high grade), HER2 with trastuzumab, HER2 without trastuzumab, and triple negative (TN; ER-, PR-, HER2-)...
November 1, 2015: International Journal of Radiation Oncology, Biology, Physics
A Kümmel, S Kümmel, J Barinoff, F Heitz, J Holtschmidt, W Weikel, F Lorenz-Salehi, A du Bois, P Harter, A Traut, J U Blohmer, B Ataseven
Aim: The risk of recurrence in breast cancer depends on factors such as treatment but also on the intrinsic subtype. We analyzed the risk factors for local, loco-regional and systemic recurrence, evaluated the differences and analyzed the risk of recurrence for different molecular subtypes. Material and Methods: A total of 3054 breast cancer patients who underwent surgery followed by adjuvant treatment at HSK hospital or Essen Mitte Hospital between 1998 and 2011 were analyzed. Based on immunohistochemical parameters, cancers were divided into the following subgroups: luminal A, luminal B (HER2-), luminal B (HER2+), HER2+ and TNBC (triple negative breast cancer)...
July 2015: Geburtshilfe und Frauenheilkunde
Noran Aboalela, Debra Lyon, R K Elswick, Debra Lynch Kelly, Jenni Brumelle, Harry D Bear, Colleen Jackson-Cook
While advances in therapeutic approaches have resulted in improved survival rates for women diagnosed with breast cancer, subsets of these survivors develop persistent psychoneurological symptoms (fatigue, depression/anxiety, cognitive dysfunction) that compromise their quality of life. The biological basis for these persistent symptoms is unclear, but could reflect the acquisition of soma-wide chromosomal instability following the multiple biological/psychological exposures associated with the diagnosis/treatment of breast cancer...
2015: PloS One
Masakazu Toi, Eric P Winer, John R Benson, Takashi Inamoto, John F Forbes, Gunter von Minckwitz, John F R Robertson, Stephen R Grobmyer, Ismail Jatoi, Hironobu Sasano, Ian Kunkler, Alice Y Ho, Chikako Yamauchi, Louis W C Chow, Chiun-Sheng Huang, Wonshik Han, Shinzaburo Noguchi, Mark D Pegram, Hideko Yamauchi, Eun-Sook Lee, Alexey A Larionov, Jose L B Bevilacqua, Michio Yoshimura, Tomoharu Sugie, Akira Yamauchi, Ian E Krop, Dong Young Noh, V Suzanne Klimberg
Kyoto Breast Cancer Consensus Conference, Kyoto, Japan, 18-20 February 2014 The loco-regional management of breast cancer is increasingly complex with application of primary systemic therapies, oncoplastic techniques and genetic testing for breast cancer susceptibility. Personalization of loco-regional treatment is integral to optimization of breast cancer care. Clinical and pathological tumor stage, biological features and host factors influence loco-regional treatment strategies and extent of surgical procedures...
2015: Future Oncology
D Ribnikar, J M Ribeiro, D Pinto, B Sousa, A C Pinto, E Gomes, E C Moser, M J Cardoso, F Cardoso
Breast cancer (BC) under age 40 is a complex disease to manage due to the additionally fertility-related factors to be taken in consideration. More than 90% of young patients with BC are symptomatic. Women<40 years are more likely to develop BC with worse clinicopathological features and more aggressive subtype. This has been frequently associated with inferior outcomes. Recently, the prognostic significance of age<40 has been shown to differ according to the BC subtype, being associated with worst recurrence-free survival (RFS) and overall survival (OS) for luminal BC...
April 2015: Current Treatment Options in Oncology
Meena S Moran
This Review assesses the relevant data and controversies regarding the use of radiotherapy for, and locoregional management of, women with triple-negative breast cancer (TNBC). In view of the strong association between BRCA1 and TNBC, knowledge of baseline mutation status can be useful to guide locoregional treatment decisions. TNBC is not a contraindication for breast conservation therapy because data suggest increased locoregional recurrence risks (relative to luminal subtypes) with breast conservation therapy or mastectomy...
March 2015: Lancet Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"